Skip to content
TrialScanner

NCT04579380

Basket Study of Tucatinib and Trastuzumab in Solid Tumors With HER2 Alterations

Phase 2Active, not recruitingPFELead

Registry record

Lead sponsor
Seagen, a wholly owned subsidiary of Pfizer
Conditions
Uterine Neoplasms; Uterine Cervical Neoplasms; Biliary Tract Neoplasms; Urologic Neoplasms; Carcinoma, Non-Small-Cell Lung
Primary completion
Nov 1, 2023Actual
Completion
Locked
Start
Locked
Enrollment
Locked
Interventions
Locked
Study type
Locked
Results on the registry
Locked
Record last updated
Locked

Open NCT04579380 on ClinicalTrials.gov

Enrollment, interventions, the start and completion dates and the change history are locked on 1 row here. Included with TrialScanner ($9.99 a month) and Signal8 Pro.

Unlock with TrialScanner

Recorded changes

0 changes recorded for this trial. The history, with each previous value, is part of TrialScanner.

Tracking since Nov 12, 2026. Changes before that date are not known to TrialScanner.

    NCT04579380: Basket Study of Tucatinib... | TrialScanner